Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI scores Myomo, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Myomo, Inc. is a small-cap company with a market capitalization of $48M. It ranks number 17 by market capitalization among the 26 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
For MYO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MYO included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
| Metric | MYO | Rank |
|---|---|---|
| Market Cap | $48M | 17/26 |
| P/B Ratio | 8.22x | 5/20 |
| EPS | $-0.35 | – |
| Book Value/Share | $0.15 | – |
| Revenue/Share | $1.09 | – |
| FCF/Share | $-0.18 | – |
| Metric | MYO | Rank |
|---|---|---|
| ROE | -248.9% | 16/19 |
| ROA | -41.0% | 13/19 |
| ROIC | -47.3% | 16/21 |
| Gross Margin | 68.3% | 6/19 |
| Operating Margin | -27.1% | 13/20 |
| Net Margin | -33.5% | 13/18 |
| EBT Margin | -32.5% | 13/20 |
| Tax Rate | -3.1% | – |
| Metric | MYO | Rank |
|---|---|---|
| Current Ratio | 2.31x | 16/24 |
| Quick Ratio | 2.01x | 9/21 |
| D/E Ratio | 5.06x | 3/23 |
| Financial Leverage | 6.06x | 3/23 |
| Interest Coverage | -5.4x | 11/20 |
| Working Capital | $14M | 16/24 |
| Metric | MYO | Rank |
|---|---|---|
| Operating Cash Flow | -$7M | 17/24 |
| Free Cash Flow | -$7M | 12/15 |
| Capital Spending | -$170K | 4/15 |
| FCF/Sales | -16.8% | 13/15 |
| CapEx/Sales | 0.4% | 12/15 |
| Metric | MYO | Rank |
|---|---|---|
| Asset Turnover | 1.22x | 4/17 |
| Receivables Turnover | 8.8x | 3/16 |
| Inventory Turnover | 0.1x | 21/21 |
| Fixed Assets Turnover | 21.8x | 4/18 |
| Days Sales Outstanding | 42 days | 14/16 |
| Days Inventory | 7769 days | 1/21 |
| Payables Period | 18423 days | 1/18 |
| Cash Conversion Cycle | -10612 days | 14/14 |
| Metric | MYO | Rank |
|---|---|---|
| Total Revenue | $43M | 12/18 |
| Operating Income | -$12M | 15/24 |
| Net Income | -$15M | 12/20 |
| R&D Expense | $6M | 15/21 |
| SG&A Expense | $40M | 13/21 |
| Cost of Goods Sold | $150K | 21/21 |
| Metric | MYO | Rank |
|---|---|---|
| Shares Outstanding | 40M | – |
| Total Current Assets | $25M | 69.4% of assets |
| Cash & Short-term Investments | $11M | 31.7% of assets |
| Accounts Receivable | $5M | 14.0% of assets |
| Inventory | $3M | 9.0% of assets |
| Total Liabilities | $30M | 83.5% of assets |
| Short-term Debt | $3M | 8.7% of assets |
Companies classified under the same SEC industry code as Myomo, Inc. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 26 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MYO Myomo, Inc. | $48M | |
| ISRG Intuitive Surgical Inc | $156.96B | |
| STE Steris Plc | $24.60B | |
| ZBH Zimmer Biomet Holdings, Inc. | $20.38B | |
| SNN Smith & Nephew Plc | $13.67B | |
| ALGN Align Technology Inc | $11.79B | |
| MSA Msa Safety Inc | $6.56B | |
| ESTA Establishment Labs Holdings Inc. | $2.00B | |
| ENOV Enovis Corp | $1.57B | |
| CDRE Cadre Holdings, Inc. | $1.40B | |
| AVR Anteris Technologies Global Corp. | $555M | |
| SMTI Sanara Medtech Inc. | $290M | |
| INGN Inogen Inc | $160M | |
| LAKE Lakeland Industries Inc | $89M | |
| NTRB Nutriband Inc. | $68M | |
| APT Alpha Pro Tech Ltd | $56M | |
| COCH Envoy Medical, Inc. | $55M | |
| MLSS Milestone Scientific Inc. | $27M | |
| LFWD Lifeward Ltd. | $16M | |
| CUPR Cuprina Holdings (Cayman) Ltd | $12M | |
| UEEC United Health Products, Inc. | $10M | |
| RGNT Regentis Biomaterials Ltd. | $8M | |
| CLGN Collplant Biotechnologies Ltd | $7M | |
| BBLG Bone Biologics Corp | $1M | |
| FEED Envue Medical, Inc. | $240K | |
| RBOT Vicarious Surgical Inc. | $10K |
Myomo Inc (MYO) is set to release its Q2 2025 earnings on Aug 11, 2025. The consensus estimate for Q2 2025 revenue is $9.15 million, and the earnings are expected to come in at -$0.11 per share. The ...
Founded in the USA and public since June 12, 2017, Myomo Inc operates in the medical devices sector, focusing on developing myoelectric orthotics for individuals with neuromuscular disorders. Its ...
(NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today ...
Our AI scores Myomo, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For MYO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Myomo, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
26 issuers in our coverage, MYO included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
